Organoid Sciences
Latest round
- Series B
Last raised
- Jan 2022
Total raised
- $39M
Investors
- 10
About Organoid Sciences
Based in Seongnam, South Korea, and founded in 2018, Organoid Sciences operates as a biotechnology company that develops new drugs for incurable disease by by utilizing organoids, which is a type of stem cell that can reproduce human organs. In 2020, Organoid Sciences was selected for stem cell regeneration medical project by the Ministry of Health and Welfare. The company's current CEO is Jongman Yu. Organoid Sciences engages in the R&D of drug development platform for treating incurable diseases. Organoid Sciences uses organoid based regeneration technology that can reproduce human organs such as pancreases, liver, etc. The company has also developed technologies for ADIO platform based immune assessment and infectious disease analysis through microbiome therapy.
Who invested in Organoid Sciences
10 investors across 3 rounds
See all investors in Organoid Sciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Organoid Sciences
Who invested in Organoid Sciences?
Organoid Sciences has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Organoid Sciences raised?
Organoid Sciences has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Organoid Sciences last raise money?
Organoid Sciences's most recent round on record is a Series B, in Jan 2022.
What does Organoid Sciences do?
Based in Seongnam, South Korea, and founded in 2018, Organoid Sciences operates as a biotechnology company that develops new drugs for incurable disease by by utilizing organoids, which is a type of stem cell that can reproduce human organs.
Where is Organoid Sciences headquartered?
Organoid Sciences is headquartered in Seongnam, South Korea.
Which VCs invest in companies like Organoid Sciences?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Organoid Sciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Organoid Sciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.